NeoVax(MI) vaccine developed by Dana-Farber Cancer Institute could be approved soon with promising results in boosting immune response in melanoma patients
Lara Maior
Health
Vyacheslav Lopatin / Alamy / Profimedia
Always see our news on Google
The clinical trial of the personalized vaccine NeoVax(MI) has shown promising results in the treatment of melanoma, generating a strong immune response. The vaccine contains patient-specific neoantigens and is administered together with standard immunotherapies such as nivolumab and ipilimumab. Scientists observed an increase in immune cells after vaccination, indicating effective immune activation. This innovative approach could significantly improve treatments for skin cancer.
Sources
Vaccinul contra unui tip agresiv de cancer, la un pas de a intra pe piață. Rezultatele remarcabile dau speranțe pacienților
Consiliul Concurenței analizează tranzacţia prin care Mehiläinen Oy preia rețeaua de centre mediale Regina Maria
Consiliul Concurenţei analizează preluarea Grupului Regina Maria de către Mehiläinen Oy
Latest News
13:32
A Russian soldier opened fire on comrades and some civilians in Sevastopol, Crimea / Four people died, and four others were injured.
13:29
Automotive suppliers are losing more jobs than large manufacturers, and new investments are shifting towards electric vehicles.
13:28
Prime Minister Vasile Tofan considers the visit of the delegation of the Ministry of Agriculture from Afghanistan to Moldova unacceptable, resulting from an evaluation error.
13:20
Automotive suppliers are losing more jobs than large manufacturers, and new investments are shifting towards electric vehicles.
13:17
Designer John Galliano will have a retrospective at the Metropolitan Museum of Art in New York, starting in May 2027. The exhibition will analyze his career and past controversies.
See more news
NEWS ON THE SAME TOPICS
.webp)
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
